IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.
IPO Year: 2013
Exchange: NASDAQ
Website: ivericbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2023 | Buy → Neutral | Guggenheim | |
| 11/10/2022 | $30.00 → $20.00 | Buy → Hold | Jefferies |
| 10/17/2022 | Sell → Neutral | B. Riley Securities | |
| 9/6/2022 | $12.00 → $8.00 | Neutral → Sell | B. Riley Securities |
| 8/2/2022 | $20.00 | Buy | UBS |
| 6/8/2022 | $30.00 | Buy | Guggenheim |
| 6/8/2022 | $18.00 | Buy | BofA Securities |
| 5/12/2022 | $12.00 | Neutral | B. Riley Securities |
| 3/22/2022 | $27.00 | Buy | Jefferies |
| 3/3/2022 | $27.00 | Outperform | Robert W. Baird |
TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary. The completion of t
IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on July 3, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of 124,860 restricted stock units for shares of the Company's common stock. The restric
IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on May 19, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of 15,745 restricted stock units for shares of the Company's common stock. The restr
IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on May 19, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to 63 newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of 339,976 restricted stock units for shares of the Company's common stock. The first t
-Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- TOKYO and PARSIPPANY, N.J., April 30, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Iveric bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement un
-Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and IVERIC Bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio"))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a w
- Post-hoc analysis from the GATHER trials, for the first time, signals that reduced rate of vision loss in patients receiving avacincaptad pegol (ACP) was correlated with reduced geographic atrophy (GA) growth - - Post-hoc time-to-event analyses signal fewer patients receiving ACP had 10-, 15- and 20-letter losses from baseline at two consecutive visits up to 12 months compared to sham - IVERIC bio, Inc. (NASDAQ:ISEE) today announced new findings from exploratory analyses of data for avacincaptad pegol (ACP), which were presented today at the 2023 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), in New Orleans. This press release features multimedia.
IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on April 3, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of non-statutory stock options to purchase 166,000 shares of the Company's common st
IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on March 1, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of non-statutory stock options to purchase 107,000 shares of the Company's common sto
- FDA Accepts Filing of New Drug Application and Grants Priority Review for Avacincaptad Pegol (ACP) for the Treatment of Geographic Atrophy; PDUFA Goal Date is August 19, 2023 - - Post-hoc Time-to-Event Analysis of ACP GATHER Trials Signals up to 59% Risk Reduction in Rate of Vision Loss Compared to Sham at 12 Months – - Commercial Launch Preparations for ACP Continue to Accelerate – - Conference Call and Webcast Today, March 1, 2023, at 8:00 a.m. ET - IVERIC bio, Inc. (NASDAQ:ISEE) today announced financial and operating results for the fourth quarter and full year ended December 31, 2022 and provided a general business update. "In 2022, we successfully delivered a banner year with a
4 - IVERIC bio, Inc. (0001410939) (Issuer)
4 - IVERIC bio, Inc. (0001410939) (Issuer)
4 - IVERIC bio, Inc. (0001410939) (Issuer)
4 - IVERIC bio, Inc. (0001410939) (Issuer)
4 - IVERIC bio, Inc. (0001410939) (Issuer)
4 - IVERIC bio, Inc. (0001410939) (Issuer)
4 - IVERIC bio, Inc. (0001410939) (Issuer)
4 - IVERIC bio, Inc. (0001410939) (Issuer)
4 - IVERIC bio, Inc. (0001410939) (Issuer)
4 - IVERIC bio, Inc. (0001410939) (Issuer)
TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary. The completion of t
-Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- TOKYO and PARSIPPANY, N.J., April 30, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Iveric bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement un
-Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and IVERIC Bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio"))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a w
IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its fourth quarter and full year 2022 financial and operating results on Wednesday, March 1, 2023. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update. To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 1375589. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours foll
- Reported Positive GATHER2 Results for Avacincaptad Pegol in Geographic Atrophy - - Planned NDA Submission Moved Up to End of This Year - - Received Favorable Feedback from FDA on Intermediate AMD Development Plan - - Conference Call and Webcast Today, November 3, 2022, at 8:00 a.m. ET - IVERIC bio, Inc. (NASDAQ:ISEE) today announced financial and operating results for the third quarter ended September 30, 2022 and provided a general business update. "With the positive data from our GATHER2 clinical trial reported in the third quarter reinforcing the positive data from GATHER1, avacincaptad pegol (ACP) became the first and only investigational therapy in geographic atrophy (GA) to ach
IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update. To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 8170771. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the liv
- Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area - - Statistically Significant Result with Favorable Safety Profile - - Post-hoc Analysis of U.S. Patients: 25.5% Reduction (p-value = 0.0037) Using Square Root Transformation; 32.0% Reduction (p-value = 0.0033) Using Observed GA Area - - Plan to Submit New Drug Application to the FDA by the End of the First Quarter 2023 - - Conference Call and Webcast Today, September 6, 2022 at 8:00am ET - IVERIC bio, Inc. (NASDAQ:ISEE) today announced positive topline results from GATHER2, th
- Zimura® GATHER2 Topline Data Expected in September of this Year- - GATHER2 Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate of 92.5% – - Agreement for up to $250 Million in Non-dilutive Debt Financing Secured - - Exclusive License Entered into for Sustained Release Delivery Technology for Zimura® - - Conference Call and Webcast Today, July 26, 2022, at 8:00 a.m. ET – IVERIC bio, Inc. (NASDAQ:ISEE) today announced financial and operating results for the second quarter ended June 30, 2022 and provided a general business update. "We are excited to share that today marks one year since we completed patient enrollment of GATHER2, our second Phase
IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its second quarter 2022 financial and operating results on Tuesday, July 26, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update. To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 0932671. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the live c
- Zimura® GATHER2 Topline Data Expected in the Third Quarter of this Year- - GATHER2 Trial Completion at 94% for Year One; Patient Retention Continues to Exceed Expectations with a Target 12-Month Injection Fidelity Rate of Greater than 90% – - U.S. Patent Covering Methods of Treating GA with Zimura Granted by USPTO – - Conference Call and Webcast Today, May 4, 2022, at 8:00 a.m. ET – IVERIC bio, Inc. (NASDAQ:ISEE) today announced financial and operating results for the first quarter ended March 31, 2022 and provided a general business update. "During the first quarter, we continued the momentum of 2021 for GATHER2, our second Phase 3 clinical trial for Zimura® (avacincaptad pegol), a
15-12G - IVERIC bio, Inc. (0001410939) (Filer)
EFFECT - IVERIC bio, Inc. (0001410939) (Filer)
25-NSE - IVERIC bio, Inc. (0001410939) (Subject)
S-8 POS - IVERIC bio, Inc. (0001410939) (Filer)
S-8 POS - IVERIC bio, Inc. (0001410939) (Filer)
S-8 POS - IVERIC bio, Inc. (0001410939) (Filer)
S-8 POS - IVERIC bio, Inc. (0001410939) (Filer)
S-8 POS - IVERIC bio, Inc. (0001410939) (Filer)
S-8 POS - IVERIC bio, Inc. (0001410939) (Filer)
S-8 POS - IVERIC bio, Inc. (0001410939) (Filer)
– Highly-Recognized Operational Executive and Strategic Advisor to Biotechnology Companies with a Proven Track Record – IVERIC bio, Inc. (NASDAQ:ISEE) announced today the appointment of Tony Gibney to Executive Vice President and Chief Business and Strategy Officer, effective December 13, 2021. Mr. Gibney is an experienced biotechnology executive and former investment banker. Mr. Gibney brings over 25 years of experience dedicated to advising biotechnology companies in the U.S. and Europe on corporate matters such as business strategy, collaboration transactions, financings, and mergers and acquisitions. As a biotechnology executive, Mr. Gibney completed multiple strategic transactions, an
– Former U.S. Franchise Head of Ophthalmics at Novartis Brings a Proven Track Record in Major Retinal Product Launches – IVERIC bio, Inc. (NASDAQ:ISEE) announced today the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Mr. Simms joins Iveric Bio from Novartis, where he successfully managed commercial operations for the U.S. Ophthalmics Franchise, launching BEOUV® (brolucizumab injection) for wet age-related macular degeneration (AMD). Before Novartis, he served as marketing lead for the Genentech ophthalmology business which included creating a new brand positioning and launching a new campaign for Lucentis® (ranibizumab in
NEW YORK--(BUSINESS WIRE)--IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on January 4, 2021, the Company granted non-statutory stock options to purchase an aggregate of 28,000 shares of the Company’s common stock to two newly hired, non-executive employees. These grants were made pursuant to the Company’s 2019 Inducement Stock Incentive Plan, were approved by the Company’s compensation committee pursuant to a delegation by the Company’s board of directors, and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The stock options h
Submission status for IVERIC BIO, INC.'s drug IZERVAY (ORIG-1) with active ingredient AVACINCAPTAD PEGOL has changed to 'Approval' on 08/04/2023. Application Category: NDA, Application Number: 217225, Application Classification: Type 1 - New Molecular Entity
SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)
SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)
SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)
SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)
SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)
SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)
SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)
SC 13G - IVERIC bio, Inc. (0001410939) (Subject)
SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)
SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)
Guggenheim downgraded IVERIC bio from Buy to Neutral
Jefferies downgraded IVERIC bio from Buy to Hold and set a new price target of $20.00 from $30.00 previously
B. Riley Securities upgraded IVERIC bio from Sell to Neutral
B. Riley Securities downgraded IVERIC bio from Neutral to Sell and set a new price target of $8.00 from $12.00 previously
UBS initiated coverage of IVERIC bio with a rating of Buy and set a new price target of $20.00
Guggenheim initiated coverage of IVERIC bio with a rating of Buy and set a new price target of $30.00
BofA Securities initiated coverage of IVERIC bio with a rating of Buy and set a new price target of $18.00
B. Riley Securities initiated coverage of IVERIC bio with a rating of Neutral and set a new price target of $12.00
Jefferies initiated coverage of IVERIC bio with a rating of Buy and set a new price target of $27.00
Robert W. Baird initiated coverage of IVERIC bio with a rating of Outperform and set a new price target of $27.00